APA

Wang L., Qiu X., Gui Y., Xu Y., Gober H. & Li D. (20160418). Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α. : Drug design, development and therapy.

Chicago

Wang Ling, Qiu Xue-Min, Gui Yu-Yan, Xu Ying-Ping, Gober Hans-Jürgen and Li Da-Jin. 20160418. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α. : Drug design, development and therapy.

Harvard

Wang L., Qiu X., Gui Y., Xu Y., Gober H. and Li D. (20160418). Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α. : Drug design, development and therapy.

MLA

Wang Ling, Qiu Xue-Min, Gui Yu-Yan, Xu Ying-Ping, Gober Hans-Jürgen and Li Da-Jin. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α. : Drug design, development and therapy. 20160418.